Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mannkind Corp (NQ: MNKD )

5.796 +0.086 (+1.51%)
Streaming Delayed Price Updated: 12:15 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mannkind Corp

< Previous 1 2 Next >
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
From MannKind
Via GlobeNewswire
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
From MannKind
Via GlobeNewswire
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
From MannKind
Via GlobeNewswire
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 5:00 p.m. (ET) 
From MannKind
Via GlobeNewswire
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
From MannKind
Via GlobeNewswire
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
From MannKind
Via GlobeNewswire
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
MannKind Repays Certain Debt Obligations
From MannKind
Via GlobeNewswire
MannKind Announces CFO Transition
From MannKind
Via GlobeNewswire
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
From MannKind
Via GlobeNewswire
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder) 
From MannKind
Via GlobeNewswire
MannKind Corporation Announces Participation at Upcoming Conferences
From MannKind
Via GlobeNewswire
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 5:00 p.m. (ET) 
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
From MannKind
Via GlobeNewswire
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
From MannKind
Via GlobeNewswire
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
From MannKind
Via GlobeNewswire
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
From MannKind
Via GlobeNewswire
MannKind Corporation Reports 2023 Third Quarter Financial Results
From MannKind
Via GlobeNewswire
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
From MannKind
Via GlobeNewswire
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
From MannKind
Via GlobeNewswire
MannKind Corporation Announces Participation at Upcoming Conferences
From MannKind
Via GlobeNewswire
MannKind Corporation Reports 2023 Second Quarter Financial Results
From MannKind
Via GlobeNewswire
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
From MannKind
Via GlobeNewswire
MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
From MannKind
Via GlobeNewswire
Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
From MannKind
Via GlobeNewswire
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
From MannKind
Via GlobeNewswire
CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results
Conference Call to Begin Today at 5:00 p.m. (ET) 
From MannKind
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.